Navigation Links
Katherine A. High, M.D., to present 2013 American Society of Hematology E. Donnall Thomas Lecture
Date:8/1/2013

(WASHINGTON, August 1, 2013) The American Society of Hematology (ASH) will honor Katherine A. High, MD, of the Howard Hughes Medical Institute and The Children's Hospital of Philadelphia with the 2013 E. Donnall Thomas Lecture and Prize for her unparalleled work to identify the molecular basis of hemophilia and to develop novel genetic therapies to treat the disorder. Named for the late Nobel Prize laureate and past Society president E. Donnall Thomas, MD, this lectureship and prize recognizes pioneering research achievements in hematology that have helped move the field forward.

Dr. High will present her lecture, "Sailing to Ithaca: Gene Therapy's Odyssey from Investigational Agent to Therapeutic Product," at 9:00 a.m. on Monday, December 9, at the 55th ASH Annual Meeting and Exposition in New Orleans. Her lecture will explore the use of gene therapies for the treatment of inherited disorders, discussing the therapeutic successes of laboratory and small-scale clinical studies conducted over the last two decades as well as the obstacles that remain to bring this seemingly straightforward yet extremely nuanced concept to successful clinical application. During her lecture Dr. High will also discuss the sustained clinical improvements yielded in the setting of inherited retinal degenerative diseases and of hemophilia B by the use of in vivo gene transfer with adeno-associated virus (AAV) vectors. She will reflect on how a rigorous understanding of the interaction of AAV vectors with the human immune response, and other homeostatic mechanisms, has allowed investigators to harness the power of gene identification and gene delivery vectors to provide long-lasting therapeutic outcomes for previously incurable diseases.

As a leading expert in gene therapy of hemophilia, Dr. High has dedicated her career to bringing this novel and complex concept to fruition. Her work has ranged from basic biochemical investigations of clotting factors, virology of the AAV viruses as relevant to vector design, dissection of the human immune response to vector and transgene proteins, development of predictive large animal models, and iterative careful and highly instructive clinical trials. Her more than 15 years of investigation regarding the feasibility of gene therapy for hemophilia has culminated in successful clinical studies utilizing AAV vector-mediated gene transfer for the treatment of hemophilia B.

Dr. High is a Howard Hughes Medical Institute Investigator, the William H. Bennett Professor of Pediatrics at the University of Pennsylvania School of Medicine, and an attending physician at the Children's Hospital of Philadelphia. She received her medical degree from the University of North Carolina School of Medicine and completed her Hematology fellowship at Yale University School of Medicine. Dr. High was named as a Howard Hughes Medical Institute Investigator in 2003 and is also an elected member of both the Institute of Medicine and the American Academy of Arts & Sciences. She is a member and former Councillor of ASH, a former president of the American Society of Gene and Cell Therapy, and a member of the International Society of Thrombosis and Hemostasis.

"Dr. High is unquestionably a leader in gene therapy and has made remarkable, ground-breaking contributions to the field, demonstrating creativity, determination, and the ability to overcome numerous obstacles," said ASH President Janis L. Abkowitz, MD, of the University of Washington. "Through her countless discoveries, Dr. High has transformed the notion of utilizing genetically engineered mechanisms for treatment of incurable inherited disorders from a distant vision to reality."


'/>"/>

Contact: Kaitlin Bressler
202-552-4925
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares
2. U.S. Health Care Spending High, But Quality Lags: Report
3. Evolution May Explain Runners High, Study Says
4. Global Tobacco Use Remains High, Survey Finds
5. Childhood Vaccination Rates Remain High, CDC Says
6. Edith Mitchell, M.D., FACP, named 2012 recipient of ASCO Humanitarian Award
7. ASH awards Timothy J. Ley, M.D., with 2012 E. Donnall Thomas Lecture and Prize
8. ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize
9. ASH honors David Ginsburg, M.D., and Richard Aster, M.D., with 2012 Henry M. Stratton Medal
10. Penn Medicines Daniel J. Rader, M.D., receives AHAs Clinical Research Prize
11. Richard Mayeux, M.D., M.S., elected Fellow of AAAS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist ... Leaders to Know in 2016 . The list consists of physicians establishing, leading and ... establish this list. , An Ambulatory Surgery Center, also known as an ASC, ...
(Date:2/12/2016)... ... 12, 2016 , ... Miami Dental Specialists is excited to bring patients the ... Beginning in January, Miami Dental Specialists will offer the non-metal implants as a safe, ... to be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge technology ...
(Date:2/12/2016)... Grants Pass, OR (PRWEB) , ... February 12, ... ... website contains an article about foods choices that promote eye health. These articles ... optimal vision health. Water and health advocate Sharon Kleyne endorses every one of ...
(Date:2/12/2016)... ... February 12, 2016 , ... A lot has been reported about the ... has access to health and wellness resources most Americans could ever dream of having ... has a schedule as frenetic as the U.S. President. , In honor of ...
(Date:2/12/2016)... Texas (PRWEB) , ... February 12, 2016 , ... Yisrayl ... a revealing article this week that uncovers what he says are the real facts ... stories of the Bible from parents and Sunday school teachers, and Yisrayl says there ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
(Date:2/11/2016)... 11, 2016 Stem cells are primitive cells ... self-renewal and the capacity to differentiate into mature cell ... as the first mouse embryonic stem cells were derived ... 1995 that the first culturing of embryonic stem cells ... not produced until 2006 As a result of these ...
(Date:2/11/2016)... -- Kindred Biosciences, Inc. (NASDAQ: KIN ), a biopharmaceutical ... pets, today announced the submission to FDA of the ... (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline results ... the control of pyrexia (fever) in horses were recently ... --> The Chemistry, Manufacturing, and Controls technical ...
Breaking Medicine Technology: